Last reviewed · How we verify
NCT01791088
Sirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
Phase 1 trial testing sirolimus in Unspecified Adult Solid Tumor, Protocol Specific in 56 participants. Completed in 17 August 2018.
17 August 2018
Quick facts
| Lead sponsor | University of Chicago |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 56 |
| Start date | 13 June 2012 |
| Primary completion | 17 August 2018 |
| Estimated completion | 17 August 2018 |
| Sites | 1 location across United States |
Drugs / interventions tested
- sirolimus (sirolimus) — full drug profile →
- pharmacological study — full drug profile →
- laboratory biomarker analysis — full drug profile →
Conditions studied
- Unspecified Adult Solid Tumor, Protocol Specific — all drugs for Unspecified Adult Solid Tumor, Protocol Specific →
- Unspecified Childhood Solid Tumor, Protocol Specific — all drugs for Unspecified Childhood Solid Tumor, Protocol Specific →
Sponsor
University of Chicago
Who can join
12 and older, any sex, with Unspecified Adult Solid Tumor, Protocol Specific or Unspecified Childhood Solid Tumor, Protocol Specific. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical trial studies sirolimus in treating patients with solid tumors that are metastatic or cannot be removed by surgery. Sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01791088
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of sirolimus
Trials testing the same drug.
- NCT03866681 — Sirolimus Combined With Low-dose Warfarin for the Treatment of Refractory PNH · Phase 4 · unknown
- NCT03765944 — Bioequivalence Study of NPC-12 (Sirolimus) Granules and Tablets · Phase 1 · completed
- NCT04161144 — Enhancing Self Regulation Among Smokers · Phase 2 · completed
- NCT03504241 — Tolerance by Engaging Antigen During Cellular Homeostasis · Phase 1 · completed
- NCT03217669 — Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy · Phase 1 · unknown
Other recruiting trials for Unspecified Adult Solid Tumor, Protocol Specific
Currently open trials in the same condition.
- NCT02112565 — RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Stand · Phase 1 · active not recruiting
- NCT02293954 — Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer · NA · active not recruiting
- NCT00477958 — Assessment Tool for Older Patients With Cancer · NA · active not recruiting
Other University of Chicago trials
Trials by the same sponsor.
- NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
- NCT07354100 — Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy · Phase 1, PHASE2 · not yet recruiting
- NCT06446661 — Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia · NA · not yet recruiting
- NCT07179315 — A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Tr · Phase 2 · not yet recruiting
- NCT07126561 — Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01791088 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Chicago
- Last refreshed: 22 April 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01791088.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing